Stillbirth more frequent in women with HIV in UK than in general population

nam/aidsmap, 01 August 2017

The stillbirth rate among women living with HIV in the UK and Ireland from 2007 to 2015 was more than twice that of the general population, Graziella Favarato, presenting on behalf of the National Study of HIV in Pregnancy and Childhood (NSHPC), told participants at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris last week.

Most women originated from a sub-Saharan African country, accounting for 0.9% of stillbirths (71/7752) while stillbirth among women from Europe or westernised countries accounted for 0.4% (8/2004).

Australian recommendations for the management of hepatitis C infection – app & website

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, July 2016

Chronic hepatitis C virus (HCV) infection is a major public health challenge for Australia, affecting approximately 230,000 people who are at risk of progressive liver fibrosis leading to cirrhosis, liver failure and hepatocellular carcinoma (HCC). The burden of liver disease due to HCV is projected to triple by 2030. The introduction of direct-acting antiviral (DAA) therapies for HCV that are highly effective and well tolerated is a major medical advance. All Australians living with HCV should now be considered for antiviral therapy.

The Australian recommendations for the management of hepatitis C virus infection: a consensus statement 2016 [PDF] was prepared by an expert panel representing the Gastroenterological Society of Australia (Australian Liver Association), the Australasian Society for Infectious Diseases, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, the Australasian Hepatology Association, Hepatitis Australia and the Royal Australian College of General Practitioners.

It provides guidance on epidemiology, models of care, diagnosis, pre-treatment assessment, monitoring and treatment. It provides guidance on epidemiology, models of care, diagnosis, pre-treatment assessment, monitoring and treatment.

  • HCV Consensus Statement website here
  • Download the app (suitable for all Android mobile devices) from Google Play. Apple iTunes version available soon.